Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...
Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...
The FDA approved Spravato for those battling depression and has seen little to no improvement from two types of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback